P/E at 34.56 vs Industry's 36.81: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: A Slight Discount in a Premium Sector

The stock’s P/E ratio of 34.56 stands at approximately 6.2% below the industry average of 36.81, indicating a modest valuation discount relative to its peers. This is notable given the sector’s overall premium valuation, driven by robust growth expectations and innovation in pharmaceuticals and biotechnology. The discount suggests that Sun Pharmaceutical Industries Ltd may be perceived as less richly valued despite its large-cap status and market cap of ₹4,34,231.64 crores.

Such a valuation gap often reflects investor caution or concerns about near-term earnings growth or competitive pressures. However, the stock’s P/E remains elevated compared to broader market averages, underscoring the sector’s premium nature. Sun Pharma’s valuation thus balances between sector optimism and selective investor scrutiny — what is the current rating?

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple timeframes reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 10.61% gain, significantly outperforming the Sensex’s 10.56% loss during the same period. This outperformance extends to longer horizons, with three-year and five-year returns of 56.14% and 119.01% respectively, well ahead of the Sensex’s 10.03% and 23.25% gains.

However, the short-term trend is less encouraging. The stock has declined by 3.01% over the past three months, underperforming the Sensex’s 5.84% fall but still negative. The one-month return of -6.25% also trails the Sensex’s -5.87%. Even the one-week performance shows a sharper decline of 2.33% compared to the Sensex’s 1.56% drop. This recent weakness contrasts with the longer-term strength and suggests a shift in momentum — is this a temporary correction or a sign of deeper challenges?

Moving Average Configuration: Mixed Technical Signals

The technical picture for Sun Pharmaceutical Industries Ltd is equally nuanced. The stock currently trades above its 200-day moving average, a long-term bullish indicator suggesting underlying strength. However, it remains below its 5-day, 20-day, 50-day, and 100-day moving averages, signalling short to medium-term weakness and a potential consolidation phase.

This configuration often points to a recent bounce within a larger downtrend or a pause before a possible trend reversal. The stock’s two-day consecutive fall, resulting in a cumulative decline of 2.23%, reinforces the cautious technical stance. The opening price of ₹1818.55 has held steady intraday, but the inability to break above shorter-term moving averages may limit near-term upside — is this a genuine recovery or a relief rally that will fade at the 50 DMA?

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced mixed results recently, with a blend of positive, flat, and negative performances across constituent stocks. The sector’s average P/E of 36.81 reflects sustained investor confidence in long-term growth prospects despite short-term volatility. Sun Pharmaceutical Industries Ltd’s slightly lower P/E ratio suggests a more cautious valuation stance compared to some peers.

Sector-wide challenges such as regulatory scrutiny, pricing pressures, and competitive innovation cycles continue to influence stock valuations and performance. Against this backdrop, how does the stock’s valuation premium or discount affect its relative attractiveness?

Rating Reassessment: Previously Rated Buy

MarketsMOJO had previously assigned a Buy rating to Sun Pharmaceutical Industries Ltd, reflecting confidence in its fundamentals and growth trajectory. The rating was reassessed on 03 Sep 2026, resulting in a Hold grade with a Mojo Score of 67.0. This shift aligns with the observed valuation-performance tension and the mixed technical signals.

The reassessment takes into account the stock’s strong long-term returns, recent short-term underperformance, and its position relative to moving averages. The balance between a modest valuation discount and cautious momentum is central to this updated view — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Conclusion: A Stock Balancing Valuation and Momentum

Sun Pharmaceutical Industries Ltd presents a compelling case of valuation-performance tension within the Pharmaceuticals & Biotechnology sector. Its P/E ratio of 34.56, slightly below the industry average, contrasts with a strong one-year and longer-term return profile but recent short-term weakness. The mixed moving average configuration further underscores the stock’s current consolidation phase.

Previously rated Buy, the stock’s reassessment to Hold reflects these nuanced data points. Investors may find the valuation discount attractive, yet the recent momentum calls for caution — what is the current rating?

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →